Nationwide Special Authority initiation applications by indication for adalimumab (Amgevita and Humira), infliximab, vedolizumab and ustekinumab

OIA response

Thank you for your request dated 6 September 2023 under the Official Information Act 1982 (OIA) for information relating to adalimumab (Amgevita and Humira), infliximab, vedolizumab and ustekinumab. You requested:

2023, year to date, nationwide Special Authority initiation applications by indication for adalimumab (Amgevita and Humira), infliximab, vedolizumab and ustekinumab by; 

  • National total
  • The following Te Whatu Ora regions,
    • Northern region
    • Te Manawa Taki
    • Central region
    • Te Waipounamu
  • The following areas,
    • Auckland central
    • Counties Manukau
    • Hawkes Bay
    • Northland
    • Taranaki
    • Waitemata
    • Canterbury
    • Capital & Coast
    • Hutt Valley
    • Nelson Marlborough
    • South Canterbury
    • Southern
    • Wairarapa
    • West Coast
    • Bay Of Plenty
    • Lakes
    • Mid Central
    • Tairawhiti
    • Waikato
    • Whanganui

Please find the information for your request in the excel spreadsheet attached.

Note that where 6 or fewer people are counted, we have changed the number to "<6" as we believe this is necessary to protect the privacy of these people (section 9(2)(a) of the OIA).

We trust that this information answers your queries. Please note, you have the right to make a complaint to the Ombudsman about our response to your OIA, under section 28(3) of the OIA. Details of how to make a complaint(external link) are on the Ombudsman’s website.

To make information more freely available, we publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.